ArticlePloS one2025
Impact of predicted microbiota tryptophanase activity on Cryptosporidium parvum proliferation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Protozoa in the genus Cryptosporidium infect intestinal epithelial cells. The profile of the fecal microbiota has been shown to impact the proliferation of Cryptosporidium parvum in a mouse model of cryptosporidiosis and a reverse effect of the parasite on the microbiota has also been described. The mechanisms underlying this interaction are unknown. The lack of effective drugs and vaccines is motivating the search for pro- or prebiotics capable of increasing resistance to parasite proliferation in the gastrointestinal tract. To understand if and how the intestinal microbiota could be harnessed for this purpose, we tested if C. parvum proliferation in the mouse responds to oral administration of Escherichia coli. This bacterium was chosen because of its reported importance in mediating colonization resistance, because it encodes tryptophanase, an enzyme which converts tryptophan into indole, and because of the availability of an ampicillin-resistant strain expressing green fluorescent protein. Excretion of GFP+ E. coli in the feces was highly variable among mice, a phenomenon which is also observed with C. parvum. A positive correlation between fecal output of probiotic E. coli and C. parvum was observed. This finding may indicate that intestinal colonization with two microorganisms as different as E. coli and C. parvum responds to the same conditions in the GI tract. Consistent with an effect of the microbiota on cryptosporidiosis, the pre-infection microbiota taxonomic profile was predictive of mouse susceptibility to C. parvum. Contrary to the reported inhibitory effect of indole on C. parvum, microbiota indole production potential was positively correlated with C. parvum fecal output. The effect of cryptosporidiosis on the microbiota was characterized by an expansion of facultative anaerobes, particularly Gammaproteobacteria. This study is a first attempt to assess the proliferation in the mouse of a defined probiotic and quantify its effect on C. parvum development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.